[바이오코리아2026] 최석우 에스티팜 전무 "캐파 최대 300%↑"

ST Pharm's capacity expansion reflects oligonucleotide therapeutics shifting from rare diseases to high-volume indications like hyperlipidemia and hypertension, requiring ton-scale manufacturing. The company's 60-80% utilization strategy balances current demand fulfillment with capacity for new customers, demonstrating confidence in sustained growth. This expansion is critical as ASO and siRNA-based treatments become mainstream, making large-scale production capabilities a key competitive advantage.